AxoGen has developed a bioassay method to mimic peripheral nerve generation using sensory neurons, aiding in testing nerve graft potency for regeneration. The method involves treating nerve grafts with various conditions, affixing DRG to the graft, culturing, and analyzing nerve outgrowth. GlobalData’s report on AxoGen gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights AxoGen Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on AxoGen, AI-assisted MRI was a key innovation area identified from patents. AxoGen's grant share as of April 2024 was 32%. Grant share is based on the ratio of number of grants to total number of patents.

Testing effect of conditions on nerve outgrowth using bioassay

Source: United States Patent and Trademark Office (USPTO). Credit: AxoGen Inc

A recently granted patent (Publication Number: US11959903B2) outlines a method for testing the effect of various conditions on nerve outgrowth. The method involves treating a nerve graft with different protocols, such as submerging it in a solution with a test compound, applying radiation or heat, modifying the microstructure, dosing with outgrowth-promoting or inhibiting agents, applying electrical fields, or seeding with stem cells. A dorsal root ganglion (DRG) is affixed to one end of the nerve graft to form a test construct, which is then cultured to allow nerve outgrowth. The analysis of the test construct helps determine the amount of outgrowing nerve structure.

Furthermore, the method includes comparing analysis metrics derived from the test construct to control metrics from untreated nerve grafts to assess the effect of the study protocol. Different techniques like sectioning, staining, diffusion tensor imaging, fluorescence microscopy, mRNA extraction, and ELISA assays are employed to quantify and identify the outgrowing nerve structure. The method also specifies the use of specific proteins like ßIII-Tubulin, S100, and GAP-43 for analysis, along with the culturing period, affixing techniques, and medium composition, including Neurobasal medium, B-27, glutamine, and Nerve Growth Factor (NGF) at a concentration of about 25 ng/mL. This patent provides a detailed and systematic approach for studying nerve outgrowth under various conditions, offering valuable insights for potential therapeutic applications in nerve regeneration research.

To know more about GlobalData’s detailed insights on AxoGen, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.